Orris

Detoxification

Asking for Preferences
Reading File
Finding Sources
Finding Sources
Searching Images

liver detoxification Phase I Phase II enzymes diagram

This pathophysiology diagram illustrates the sources and biotransformation stages of Benzo[a]pyrene (B[a]P), a polycyclic aromatic hydrocarbon. The upper panel identifies three primary exposure categories: Environmental signals (medications, cosmetics, industrial emissions), Diet (vegetables, meats, eggs, cheese), and Habits (cigarette smoking). Central to the diagram is the liver, the primary site of metabolism. The lower panel outlines a four-step biotransformation process: 1) Absorption, mediated by OATPs and NTCP transporters; 2) Phase I (oxidation), where cytochrome P450 enzymes (CYPs) convert the xenobiotic into reactive, biologically active metabolites that can lead to toxicity; 3) Phase II (conjugation), involving transferases and substrates like GSH, PAPS, and UDPGA to produce hydrophilic glucuronide or sulfonic conjugates; and 4) Phase III (extrusion), where ABC and SLC transporters facilitate the elimination of biologically inactive metabolites from the cell. This diagram serves as an educational resource for toxicology and pharmacology, highlighting the dual pathways of metabolic activation (toxicity) and detoxification (elimination).

This pathophysiology diagram illustrates the sources and biotransformation stages of Benzo[a]pyrene (B[a]P), a polycyclic aromatic hydrocarbon. The upper panel identifies three primary exposure categories: Environmental signals (medications, cosmetics, industrial emissions), Diet (vegetables, meats, eggs, cheese), and Habits (cigarette smoking). Central to the diagram is the liver, the primary site of metabolism. The lower panel outlines a four-step biotransformation process: 1) Absorption, mediated by OATPs and NTCP transporters; 2) Phase I (oxidation), where cytochrome P450 enzymes (CYPs) convert the xenobiotic into reactive, biologically active metabolites that can lead to toxicity; 3) Phase II (conjugation), involving transferases and substrates like GSH, PAPS, and UDPGA to produce hydrophilic glucuronide or sulfonic conjugates; and 4) Phase III (extrusion), where ABC and SLC transporters facilitate the elimination of biologically inactive metabolites from the cell. This diagram serves as an educational resource for toxicology and pharmacology, highlighting the dual pathways of metabolic activation (toxicity) and detoxification (elimination).

Reading File
Reading File
Reading File
Reading File
Finding Sources
Loading Image
Finding Sources
Reading File
Reading File
Here is a comprehensive breakdown of liver biochemical detoxification, drawn from multiple authoritative sources.

Hepatic Detoxification: Phase I, II, and III

The liver is the primary organ responsible for converting lipophilic, potentially toxic compounds (xenobiotics, drugs, endogenous metabolites) into water-soluble forms that can be excreted. This happens in three sequential phases.

Overview

Most xenobiotics - drugs, pollutants, pesticides - are lipophilic, which helps them cross cell membranes but makes direct renal excretion impossible. The liver uses a three-phase system:
RH (lipophilic) → Phase I → ROH (primary metabolite) → Phase II → RO-Conjugate (water-soluble) → Phase III → Excretion
  • Medical Physiology, p. 1412
Xenobiotic metabolism: Phase I and Phase II reactions leading to elimination or toxicity

Phase I - Functionalization Reactions

Goal: Introduce or expose a polar functional group on the xenobiotic to make it more reactive for Phase II.
Reactions: Oxidation, reduction, hydrolysis (and sub-types: hydroxylation, dealkylation, dehalogenation)
Common thread: One atom of O₂ is inserted into the substrate (monooxygenase reaction).

The Cytochrome P450 (CYP) System

The key enzyme family in Phase I is the cytochrome P450 (CYP) superfamily - heme-containing monooxygenases located on the smooth endoplasmic reticulum (SER) of hepatocytes.
The overall reaction is:
R-H + O₂ + NADPH + H⁺ → R-OH + H₂O + NADP⁺
  • Lippincott's Biochemistry, p. 437
There are 57 human CYP genes encoding hundreds of variants. The most clinically important include:
CYP IsoformKey Substrates/Role
CYP3A4Most common drug-metabolizing CYP; statins, benzodiazepines, immunosuppressants
CYP2D6Opioids, beta-blockers, antidepressants
CYP2C9Warfarin, NSAIDs, phenytoin
CYP1A2Theophylline, caffeine, clozapine
CYP2E1Ethanol, acetaminophen, volatile anesthetics
  • Medical Physiology, p. 1412; Robbins Pathologic Basis of Disease, p. 387

Two CYP Locations

  1. Mitochondrial CYPs - involved in steroidogenesis (adrenal cortex, gonads, placenta) and vitamin D hydroxylation
  2. Microsomal CYPs (SER) - the main detoxification system for xenobiotics and drugs

Dual Outcomes of Phase I

Phase I can go two ways:
  • Detoxification: The metabolite is less toxic and more water-soluble (e.g., hydroxylated product ready for Phase II)
  • Bioactivation (toxification): The reaction generates a reactive/toxic metabolite that damages cellular components
Classic examples of bioactivation:
  • Carbon tetrachloride (CCl₄) → trichloromethyl free radical (•CCl₃) → hepatocellular necrosis
  • Benzo[a]pyrene (cigarette smoke) → DNA-binding epoxide → carcinogenesis
  • Acetaminophen → NAPQI (N-acetyl-p-benzoquinone imine) → hepatotoxicity when glutathione is depleted
Both reactions also generate reactive oxygen species (ROS) as byproducts, contributing to oxidative cell damage.
  • Robbins Pathologic Basis of Disease, p. 387-388

CYP Inducers and Inhibitors

Inducers (↑ CYP activity)Inhibitors (↓ CYP activity)
Rifampicin, phenobarbital (CYP3A4, CYP2B6)Ketoconazole, cimetidine (competitive)
Carbamazepine, phenytoinErythromycin, clarithromycin
Tobacco smoke (CYP1A)Grapefruit juice (CYP3A4 - irreversible)
St. John's Wort (hyperforin, CYP3A)Chloramphenicol
Alcohol (CYP2E1)Metronidazole
Cruciferous vegetables (CYP1A2)Fluconazole
Inducers act via nuclear receptors (AHR, PXR, CAR, PPAR-α) that bind response elements in CYP gene promoters. Genetic polymorphisms in CYP genes are also a major source of individual variation in drug metabolism.
  • Katzung's Basic and Clinical Pharmacology, p. 102; Robbins, p. 388

Phase II - Conjugation Reactions

Goal: Attach a highly polar, water-soluble moiety to the Phase I metabolite (or directly to some xenobiotics) to dramatically increase water solubility and enable excretion.
Phase II reactions are generally faster than Phase I, so they are usually the rate-limiting step only when Phase I is very slow.
Conjugation TypeEndogenous Co-substrateEnzyme (Location)Key SubstratesExamples
GlucuronidationUDP-glucuronic acid (UDPGA)UGT - UDP glucuronosyltransferase (microsomes)Phenols, alcohols, carboxylic acids, aminesMorphine, acetaminophen, diazepam, bilirubin
SulfationPAPS (phosphoadenosyl phosphosulfate)Sulfotransferase (cytoplasm)Phenols, alcohols, aromatic aminesEstrone, acetaminophen, methyldopa
Glutathione conjugationGlutathione (GSH)GSH-S-transferase (cytoplasm, microsomes)Epoxides, arene oxidesAcetaminophen (NAPQI), bromobenzene
AcetylationAcetyl-CoAN-Acetyltransferase (cytoplasm)AminesSulfonamides, isoniazid, dapsone
MethylationS-Adenosylmethionine (SAM)Transmethylases (cytoplasm)Catecholamines, phenols, aminesDopamine, epinephrine, histamine
Glycine conjugationGlycineAcyl-CoA glycinotransferase (mitochondria)Carboxylic acidsSalicylic acid, benzoic acid, bile acids
Water conjugation (EH)WaterEpoxide hydrolase (microsomes/cytoplasm)Arene oxides, alkene oxidesBenzo[a]pyrene 7,8-epoxide
  • Katzung's Basic and Clinical Pharmacology, p. 103-104

Important caveat

Phase II was historically viewed as pure detoxification, but some conjugations can generate reactive products:
  • Acyl glucuronidation of NSAIDs can produce protein-reactive acyl glucuronides
  • O-sulfation of N-hydroxyacetylaminofluorene produces a carcinogenic electrophile
  • N-acetylation of isoniazid generates a hepatotoxic metabolite
  • Katzung's Basic and Clinical Pharmacology, p. 104

Phase III - Efflux (Elimination)

After conjugation, the water-soluble product must leave the hepatocyte. This is mediated by transporter proteins on two surfaces:
  • Canalicular membrane transporters (MRP2, BSEP, MDR1/P-gp, BCRP) → conjugate excreted into bile → feces
  • Sinusoidal membrane transporters (MRP3, MRP4) → conjugate returns to blood → renal excretion in urine
  • Medical Physiology, p. 1412

Summary Diagram

Biotransformation stages of xenobiotics showing Phase I (CYP oxidation), Phase II (conjugation with GSH, PAPS, UDPGA), and Phase III (transporter-mediated elimination)

Key Clinical Points

  1. Genetic polymorphisms in CYP and transferase genes (e.g., slow vs. fast acetylators of NAT2) explain major inter-individual differences in drug efficacy and toxicity.
  2. Drug-drug interactions frequently arise from CYP induction or inhibition - rifampicin induces CYP3A4 and can render oral contraceptives ineffective.
  3. Liver disease (cirrhosis) reduces Phase I capacity (CYP expression falls), leading to drug accumulation and toxicity at normal doses.
  4. Acetaminophen toxicity is a textbook example: CYP2E1/CYP3A4 generate NAPQI (Phase I bioactivation); normally GSH conjugation (Phase II) neutralizes it, but in overdose or fasting states, GSH is depleted and NAPQI accumulates causing centrilobular necrosis.
  5. Nutrition directly affects Phase II: glucuronidation requires dietary glucose (UDPGA), methylation requires SAM (methionine, B12, folate), and glutathione synthesis requires cysteine.
This is a shared conversation. Sign in to Orris to start your own chat.